Management of bleeding emergencies: when to use recombinant activated factor VII.

摘要: Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to select group of patients who had few other treatment options. Due the apparent ability rVIIa stop bleeding, no matter what underlying cause, there is great interest in wide range bleeding patients. This article discusses and its uses variety patients, especially liver disease trauma makes suggestions for appropriate use. Although most reports on are anecdotes case series, increasing data clinical trials help guide usage.